Table 3

Summary of safety over the 6-month treatment period*

Abatacept (n = 28)Placebo (n = 28)
AEs, n (%)18 (64.3)20 (71.4)
 Discontinuations due to AEs1 (3.6)1 (3.6)
Serious AEs, n (%)1 (3.6)1 (3.6)
 Discontinuations due serious AEs00
Infections, n (%)10 (35.7)11 (39.3)
Malignancies, n (%)1 (3.6)0
Deaths, n (%)00
  • * Including a follow-up period of up to 56 days after the last dose of study drug.

  • AE, adverse event.